Nordea Investment Management AB Has $37.81 Million Holdings in Prestige Consumer Healthcare Inc. $PBH

Nordea Investment Management AB grew its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 547.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 615,215 shares of the company’s stock after purchasing an additional 520,186 shares during the period. Nordea Investment Management AB owned about 1.28% of Prestige Consumer Healthcare worth $37,811,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in PBH. Allspring Global Investments Holdings LLC grew its position in Prestige Consumer Healthcare by 4.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock worth $100,893,000 after buying an additional 70,376 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Prestige Consumer Healthcare in the 3rd quarter valued at $1,890,000. Tributary Capital Management LLC raised its holdings in Prestige Consumer Healthcare by 157.3% in the 3rd quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock valued at $23,675,000 after acquiring an additional 231,969 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Prestige Consumer Healthcare by 30.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 459,228 shares of the company’s stock valued at $28,656,000 after acquiring an additional 106,224 shares during the period. Finally, Franklin Resources Inc. lifted its position in shares of Prestige Consumer Healthcare by 51.8% during the 2nd quarter. Franklin Resources Inc. now owns 33,476 shares of the company’s stock valued at $2,673,000 after acquiring an additional 11,429 shares during the period. 99.95% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Jefferies Financial Group cut their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Hold” and an average target price of $76.50.

Insider Activity

In other news, VP Jeffrey Zerillo sold 1,000 shares of the company’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the completion of the transaction, the vice president directly owned 41,048 shares in the company, valued at approximately $2,706,294.64. This represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Trading Up 2.9%

PBH opened at $62.77 on Tuesday. The company’s 50 day moving average is $65.77 and its 200-day moving average is $63.24. Prestige Consumer Healthcare Inc. has a 1-year low of $57.25 and a 1-year high of $89.37. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The company has a market cap of $2.97 billion, a P/E ratio of 16.61, a PEG ratio of 1.92 and a beta of 0.41.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The company had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.Prestige Consumer Healthcare’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.22 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).